Erlotinib

Tarceva

Antineoplastic • EGFR tyrosine kinase inhibitor

HepatotoxicNephrotoxic

Half-life

36 hours

Protein Binding

95%

Metabolized By

CYP3A4, CYP1A2

External

Reversibly inhibits EGFR (HER1) tyrosine kinase

Drug Class

Antineoplastic

Subclass

EGFR tyrosine kinase inhibitor

Tarceva

Half-life

36 hours

Time for plasma concentration to decrease by 50%

Protein Binding

95%

Fraction bound to plasma proteins

Therapeutic Index

Wide

Margin between therapeutic and toxic doses